The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Following frontline treatment for large B-cell lymphoma (LBCL), ultrasensitive circulating tumor DNA (ctDNA) is more prognostic of disease progression than conventional PET scans
EAGLE, which stands for Exchange for Advanced Global Learning and Education, fulfills SOHO’s longstanding mission to educate and to expand global access to
The US Food and Drug Administration (FDA) received the supplemental New Drug Application for venetoclax (VENCLEXTA) and acalabrutinib (Calquence), an all-oral, fixed-duration regimen,
A real-world study assessed outcomes in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) who relapsed following transplant and observed a
Final results of the phase 3 BELLINI trial showed no improvement in overall survival (OS) for patients with multiple myeloma (MM) when venetoclax
The US Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) formulation of tocilizumab-anoh to include in the
Register today at soho.click/2025. Become a member at soho.click/join.
The US Food and Drug Administration (FDA) has accepted the supplemental biologics license application (sBLA) for lisocabtagene maraleucel (liso-cel; Breyanzi) for adults with
The new meeting offers an accessible format that meets the needs of busy hematologic oncologists, bringing the best in patient care knowledge directly
The European Commission (EC) has granted marketing authorization to the chimeric antigen receptor T-cell therapy obecabtagene autoleucel (obe-cel; AUCATZYL) for adults ages 26
